<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612260</url>
  </required_header>
  <id_info>
    <org_study_id>yl-yxb06-lcsyfa-201201</org_study_id>
    <secondary_id>2012CB518600（2012CB518606）</secondary_id>
    <nct_id>NCT01612260</nct_id>
  </id_info>
  <brief_title>Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat</brief_title>
  <official_title>Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cong-xin Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of Chinese medicine Shensong Yangxin
      capsule for the chronic cardiac dysfunction complicated with ventricular premature beats.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ventricular contractions is one of the most common arrhythmia in the patients with
      structural heart disease and heart failure, which is not only has the high incidence but also
      has a high predictive value of sudden death. The purpose of the study is to assess the
      effects of Chinese medicine Shensong Yangxin capsule for the chronic cardiac dysfunction
      complicated with ventricular premature beats, which based on the numbers of premature
      ventricular contractions in 24-hour ambulatory electrocardiogram (ECG) as the main endpoint
      of the study. Secondary endpoints are evaluation of the Shensong Yangxin capsule on cardiac
      function and quality of life. This study is a randomized, double-blind, placebo controlled,
      multi-center trial. Chronic heart failure patients(cardiac function is Class II-III)
      associated with premature ventricular contractions (premature number 720-10000 / 24h), who
      received standardized treatment for heart failure at least three months, were involved in the
      study. Patients were randomly assigned into Shensong Yangxin capsule group or placebo group,
      with the capsule administration of 4 granules t.i.d.for 12 weeks. 24-hour ambulatory ECG,
      echocardiography and evaluation of heart function were observed at baseline and 12 weeks
      after the intervention. The primary outcomes are the numbers of premature ventricular
      contractions in 24-hour ambulatory ECG, and the secondary outcomes are New York Heart
      Association (NYHA) classification, NT-proBNP, left ventricular ejection fraction (LVEF) and
      left ventricular end-diastolic dimension (LVEDD, 6 minute walking test and Minnesota living
      with heart failure questionnaire (MLHFQ).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of the Premature ventricular contractions during 24-hour ambulatory ECG</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA classification</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota living with heart failure questionnaire (MLHFQ)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walking test</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEDD</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ventricular Premature Complex</condition>
  <arm_group>
    <arm_group_label>Shensong Yangxin capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Capsule 4 granules t.i.d. po for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shensong Yangxin capsule</intervention_name>
    <description>ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks</description>
    <arm_group_label>Shensong Yangxin capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo Capsule</intervention_name>
    <description>4 granules t.i.d. po for 12 weeks</description>
    <arm_group_label>placebo Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cardiac function NYHA II~III, Left ventricular ejection fraction (LVEF)
             35%~50% tested by Modified Simpson, has a stable hemodynamics and no need to deliver
             treatment through vein

          -  To be treated by standard treatment of heart failure at least 3 months with a stable
             dosage already

          -  Ventricular premature beats: 720-10000 beats/24 hours

          -  Heart failure caused by ischemic heart disease, or dilated cardiomyopathy

        Exclusion Criteria:

          -  Subject to be expected to alive no more than 6 months

          -  Subject suffered from acute coronary syndrome in last three months (Acute myocardial
             infarction of ST segment elevation and non ST segment elevation, unstable angina

          -  To be complicated with persistent atrial fibrillation, atrioventricular conduction
             block (II degree of Type II or III degree), or acute myocarditis

          -  To be complicated with ventricular fibrillation, torsion type ventricular heartbeat
             rate, sustained ventricular tachycardia, or non sustained ventricular tachycardia with
             rapid ventricular rate and hemodynamic disorders

          -  Sinus heart rate less than 45 beats/minutes and needs to receive the pacemaker or has
             received pacemaker, or with abnormal sinus node function

          -  The hypertension, diabetes difficult to be controlled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cong-xin Huang, PH D</last_name>
    <phone>13907131546</phone>
    <email>huangcongxin@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xi Wang</last_name>
    <phone>15994207265</phone>
    <email>xiwangwhu@16..com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>changsheng Ma, PH D</last_name>
      <phone>13901357404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Freindship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yong Wang, PH D</last_name>
      <phone>13801239117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Zhongshan Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xia Mei, PH D</last_name>
      <phone>13508322668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>weifeng Wu, PH D</last_name>
      <phone>13907719960</phone>
      <email>wucna@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yue Xia, PH D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chunguang Qiu, PH D</last_name>
      <phone>13803898806</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Enshi Autonomous Region Central Hospital</name>
      <address>
        <city>Enshi</city>
        <state>Hubei</state>
        <zip>445000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuanhong Li, PH D</last_name>
      <phone>13986843863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jingzhou Central Hospital</name>
      <address>
        <city>Jingzhou</city>
        <state>Hubei</state>
        <zip>434000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xin Li, PH D</last_name>
      <phone>13872347567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Dongfeng Motor Corporation</name>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <zip>442000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>handong Yang, PH D</last_name>
      <phone>13807285189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yangyang Dai, PH D</last_name>
      <phone>15327411241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangyang Central Hospital</name>
      <address>
        <city>Xiangyang</city>
        <state>Hubei</state>
        <zip>441000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenwei Liu, PH D</last_name>
      <phone>13907279669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First College of Clinical Medical Science, China Three Gorges University</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <zip>443000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jun Yang, PH D</last_name>
      <phone>13972561866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jiangang Zou, PH D</last_name>
      <phone>13605191407</phone>
      <email>jgzou@njmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital,The Affiliated hospital of Nanjing University Medical school</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei Xu, PH D</last_name>
      <phone>13390900868</phone>
      <email>xuwei2003@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zulu Wang, PH D</last_name>
      <phone>13309824590</phone>
      <email>wangzl@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Traffic hospitals of Shandong Province</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tian Wang, PH D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liqun Wu, PH D</last_name>
      <phone>13801621534</phone>
      <email>wuliquan89@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>fang Wang, PH D</last_name>
      <phone>13621950918</phone>
      <email>onlyfang2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yunzeng Zou, PH D</last_name>
      <phone>13817702933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westchinahospital,Sichuanuniversity</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dejia Huang, PH D</last_name>
      <phone>13908181686</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>Cong-xin Huang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>ventricular premature complex</keyword>
  <keyword>Shensong Yangxin capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

